Berlin-based Tacalyx has secured €11 million in a first closing of its seed extension round from its existing international investor syndicate, including Boehringer Ingelheim Venture Fund and Kurma Partners, alongside High-Tech Gründerfonds, Eurazeo, Creathor Ventures, and Thuja Capital.
The financing comes as the biotech selects TCX-201 as its first clinical candidate. The programme, an antibody drug conjugate targeting an undisclosed Tumour Associated Carbohydrate Antigen, is being advanced for gastrointestinal cancers and other solid tumours, with the company targeting a clinical trial application in 2027.
Tacalyx said the new funding will support TCX-201 through preclinical development while also advancing its broader pipeline of antibody-based cancer therapies. The company added that it plans to expand the round with additional investors in a subsequent closing.
Tacalyx is developing therapies against Tumour Associated Carbohydrate Antigens, a class of cancer targets that has remained largely untapped in oncology. The company is building a pipeline spanning ADCs and other antibody-based modalities for multiple solid tumour indications.
The financing comes as the biotech selects TCX-201 as its first clinical candidate. The programme, an antibody drug conjugate targeting an undisclosed Tumour Associated Carbohydrate Antigen, is being advanced for gastrointestinal cancers and other solid tumours, with the company targeting a clinical trial application in 2027.
Tacalyx said the new funding will support TCX-201 through preclinical development while also advancing its broader pipeline of antibody-based cancer therapies. The company added that it plans to expand the round with additional investors in a subsequent closing.
Tacalyx is developing therapies against Tumour Associated Carbohydrate Antigens, a class of cancer targets that has remained largely untapped in oncology. The company is building a pipeline spanning ADCs and other antibody-based modalities for multiple solid tumour indications.